摘要
目的探究双歧杆菌四联活菌辅助头孢哌酮钠舒巴坦钠对重症肺炎的临床疗效。方法选取2020年2月—2021年2月在江苏省镇江市第一人民医院就诊的重症肺炎患者100例,按照随机数表法均分为对照组和观察组,各50例。对照组头孢哌酮钠舒巴坦钠治疗,观察组实施双歧杆菌四联活菌辅助头孢哌酮钠舒巴坦钠联合治疗。对比两组患者的治疗效果、肺炎严重指数评分(PSI)、急性生理与慢性健康评估评分(APACHEⅡ)、临床症状好转时间及生活质量。结果治疗后,观察组总有效率为96.00%,高于对照组4.00%,差异有统计学意义(χ^(2)=4.000,P<0.05);两组治疗前后PSI评分、APACHEⅡ评分组内对比,差异有统计学意义(P<0.05);治疗后,观察组患者的PSI评分、APACHEⅡ评分低于对照组,差异有统计学意义(t=15.193、7.387,P<0.05)。观察组患者的体温恢复正常时间、痰液颜色改变时间、WBC下降时间、CRP下降时间、PCT下降时间均少于对照组,差异有统计学意义(t=7.833、10.248、4.362、14.417、14.680,P<0.05);两组治疗前后生活质量各维度评分及总分组内对比,差异有统计学意义(P<0.05);治疗后,观察组生活质量各维度评分及总分均高于对照组,差异有统计学意义(P<0.05)。结论采用双歧杆菌四联活菌辅助头孢哌酮钠舒巴坦钠治疗重症肺炎,可提升患者的治疗效果,帮助患者提高生活质量,缩短患者的康复周期,降低患者PSI评分的同时,改善APACHEⅡ评分,建议在大范围临床推广。
Objective To investigate the clinical efficacy of Bifidobacterium tetrasporium adjuvant to cefoperazone sodium sulbactam sodium in severe pneumonia.Methods 100 patients with severe pneumonia who attended the First People’s Hospital of Zhenjiang City,Jiangsu Province,from February 2020 to February 2021 were selected.According to the random number table method,they were equally divided into control group and observation group,50 cases each.The control group was treated with cefoperazone sodium sulbactam sodium,and the observation group was treated with Bifidobacterium tetradecanoide supplemented with cefoperazone sodium sulbactam sodium.The treatment effect,pneumonia severity index score(PSI),acute physiological and chronic health assessment score(APACHEⅡ),time to improvement of clinical symptoms,and quality of life of the two groups were compared.Results After treatment,the total effective rate in the observation group was 96.00%which was higher than that in the control group 84.00%,and the difference was statistically significant(χ^(2)=4.000,P<0.05).There was a statistically significant difference between the two groups in PSI score and APACHEⅡscore before and after treatment within the group(P<0.05);the PSI score and APACHEⅡscore of patients in the observation group were lower than those in the control group after treatment,and the differences were statistically significant(t=15.193,7.387,P<0.05).The time to return to normal temperature,time to change sputum color,time to decrease WBC,time to decrease CRP,and time to decrease PCT of patients in the observation group were all less than those in the control group,and the differences were statistically significant(t=7.833,10.248,4.362,14.417,14.680,P<0.05).There was a statistically significant difference between the two groups in scores of all dimensions of quality of life and total scores before and after treatment within the group(P<0.05).After treatment,the scores of all dimensions of quality of life and total scores were higher in the observation group
作者
王纯
蔡燕
虞志新
WANG Chun;CAI Yan;YU Zhixin(Department of Critical Care Medicine,Zhenjiang First People's Hospital,Zhenjiang,Jiangsu Province,212002 China)
出处
《系统医学》
2022年第19期27-31,共5页
Systems Medicine
基金
江苏大学临床医学科技发展基金项目(JLY2021006)。
关键词
双歧杆菌四联活菌
头孢哌酮钠舒巴坦钠
重症肺炎
临床疗效
Bifidobacterium tetrakis
Cefoperazone sodium sulbactam sodium
Severe pneumonia
Clinical efficacy
